Berberine (CAS 2086-83-1): AMPK Activator for Metabolic Regulation & Inflammation

Executive Summary:
Berberine is an isoquinoline alkaloid (C₂₀H₁₈NO₄, MW 336.36) chiefly isolated from Cortex Phellodendri Chinensis, with established roles in activating AMP-activated protein kinase (AMPK) and modulating metabolic, inflammatory, and antimicrobial pathways (APExBIO). It upregulates hepatic LDL receptor (LDLR) expression in human hepatoma cells and reduces serum cholesterol in hyperlipidemic animal models (Li et al., 2025). Berberine is insoluble in water and ethanol but dissolves to ≥14.95 mg/mL in DMSO, with optimal storage below -20°C. Its anti-inflammatory effects involve modulation of the NLRP3 inflammasome and cGAS-STING pathway. APExBIO’s Berberine (N1368) is widely employed in metabolic, cardiovascular, and inflammation research.

Biological Rationale

Berberine is a natural isoquinoline alkaloid with a long history of medicinal use. It is mainly extracted from plants such as Cortex Phellodendri Chinensis and Berberis vulgaris (APExBIO). Its molecular formula is C₂₀H₁₈NO₄, and its molecular weight is 336.36 g/mol. Berberine demonstrates negligible solubility in water and ethanol but is soluble in DMSO at concentrations ≥14.95 mg/mL. It is stored as a solid at -20°C, protected from light and moisture. Berberine’s principal biological rationale centers on its documented activation of AMPK, a master regulator of energy metabolism. AMPK activation leads to improvements in glucose uptake, fatty acid oxidation, and insulin sensitivity. Additionally, Berberine modulates inflammatory responses by interfering with key signaling pathways such as the NLRP3 inflammasome and cGAS-STING axis (Li et al., 2025). These properties make Berberine a research tool in metabolic, cardiovascular, and inflammation models.

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine’s primary mechanism is the activation of AMPK. AMPK acts as a cellular energy sensor; its activation stimulates catabolic pathways that generate ATP and inhibits anabolic processes that consume ATP. Berberine increases AMPK phosphorylation (Thr172) in hepatocytes, myocytes, and adipocytes. In HepG2 and Bel-7402 human hepatoma cell lines, Berberine exposure (up to 15 μg/mL) results in dose-dependent upregulation of LDLR mRNA and protein, thus promoting hepatic clearance of LDL cholesterol. In animal models, oral Berberine at 50–100 mg/kg/day for 10 days lowers serum total and LDL cholesterol, correlating with increased hepatic LDLR expression. Berberine also attenuates inflammatory responses by downregulating NLRP3 inflammasome activation and suppressing the cGAS-STING pathway, both of which are implicated in sterile inflammation and acute kidney injury (Li et al., 2025). These mechanisms support Berberine’s multifaceted applications in metabolic disease and inflammation research. For a broader integration of mechanisms, see the systems biology discussion in "Berberine (CAS 2086-83-1): Mechanistic Leverage and Strat..."—this article extends the discussion by providing deeper evidence on inflammasome modulation.

Evidence & Benchmarks

• Berberine (CAS 2086-83-1) increases phosphorylation of AMPK at Thr172 in hepatocytes and muscle cells, enhancing glucose uptake and fatty acid oxidation (Li et al., 2025).
• In HepG2 and Bel-7402 cells, Berberine upregulates LDLR mRNA and protein in a dose-dependent manner, with maximal effects at 15 μg/mL; this is not observed in control treatments (APExBIO).
• In female golden hamsters with diet-induced hyperlipidemia, oral Berberine (50–100 mg/kg/day for 10 days) significantly reduces serum total cholesterol and LDL cholesterol (p<0.05 vs. control), paralleling increased hepatic LDLR expression (Li et al., 2025).
• Berberine inhibits NLRP3 inflammasome activation in cellular and animal models, reducing IL-1β and IL-18 secretion during sterile inflammation (Li et al., 2025).
• Berberine demonstrates negligible solubility in water or ethanol at 25°C, but dissolves in DMSO at ≥14.95 mg/mL with warming or sonication (APExBIO).

For a comparison of LDLR upregulation roles and translational applications, see "Berberine (CAS 2086-83-1): Advanced Insights into AMPK Ac..."; the current article provides updated in vivo benchmarks and specific dosing parameters.

Applications, Limits & Misconceptions

Berberine is extensively used in research on metabolic syndrome, type 2 diabetes, obesity, and cardiovascular disorders. Its anti-inflammatory actions make it valuable in studies of sterile inflammation, such as acute kidney injury (AKI). Cellular assays leverage its LDLR upregulation and AMPK activation to model hepatic lipid clearance and insulin sensitivity. In vivo, Berberine enables pharmacodynamic studies of lipid metabolism and glucose regulation. The compound’s impact on inflammasome pathways (NLRP3, cGAS-STING) also supports research on tissue injury and innate immunity. The N1368 kit from APExBIO is a widely used reference standard. For practical protocols and troubleshooting, "Berberine (CAS 2086-83-1): Reliable Solutions for Cell Vi..." offers workflow-centric guidance; this article clarifies mechanistic boundaries and evidence thresholds.

Common Pitfalls or Misconceptions

• Solubility Misunderstanding: Berberine is not water- or ethanol-soluble at room temperature; attempts to dissolve in these solvents can lead to experimental failure.
• Overestimation of Antimicrobial Potency: While in vitro antimicrobial activity is documented, Berberine is not a clinically approved antibiotic and lacks activity against many resistant strains.
• Assumption of Direct NLRP3 Inhibition: Berberine modulates rather than directly inhibits NLRP3 inflammasome assembly; effects are context- and dose-dependent.
• Ignoring Storage Protocols: Solution stability is poor; stock solutions must be kept at ≤-20°C and used promptly to avoid degradation.
• Extrapolation to Human Therapy: Most evidence is preclinical; translation to human efficacy requires careful consideration of dosing, bioavailability, and metabolism.

Workflow Integration & Parameters

Berberine (CAS 2086-83-1) from APExBIO (SKU N1368) is commonly supplied as a solid and should be dissolved in DMSO (≥14.95 mg/mL) using gentle warming (37°C) or ultrasonic agitation. Water and ethanol are not suitable solvents. Stock solutions should be aliquoted and stored below -20°C, protected from light and moisture. Long-term storage of diluted solutions is discouraged. Typical in vitro dosing ranges from 1–15 μg/mL, with maximal LDLR upregulation observed at 15 μg/mL in HepG2 and Bel-7402 cells. For animal studies, effective oral doses are 50–100 mg/kg/day over 10 days for lipid metabolism endpoints. Assays measuring AMPK phosphorylation, LDLR expression, and cytokine release (IL-1β, IL-18) are recommended. For targeted experimental workflows and troubleshooting, see "Berberine (CAS 2086-83-1): Reliable Solutions for Cell Vi..."; this article updates parameters for inflammation and metabolic crosstalk models.

Conclusion & Outlook

Berberine (CAS 2086-83-1) is a validated AMPK activator and inflammation modulator for research applications in metabolism and innate immunity. Its robust upregulation of LDLR and attenuation of NLRP3 inflammasome activity underpin its use in metabolic, cardiovascular, and acute inflammation models. APExBIO’s Berberine (N1368) sets the standard for reproducible, high-impact experiments. Ongoing research will clarify its translational potential and illuminate new molecular targets. For a broader synthesis of metabolic regulation and inflammasome crosstalk, see "Berberine (CAS 2086-83-1): Precision Modulation of Metabo..."; this article updates evidence for in vivo and mechanistic benchmarks in inflammation research.